Structure Therapeutics (NASDAQ:GPCR) Stock Price Down 7.5% – Here’s What Happened

Shares of Structure Therapeutics Inc. Sponsored ADR (NASDAQ:GPCR) fell 7.5% on Wednesday . The company traded as low as $52.10 and last traded at $51.9140. 216,549 shares traded hands during trading, a decline of 79% from the average session volume of 1,034,382 shares. The stock had previously closed at $56.15.

Analyst Upgrades and Downgrades

Several research firms have commented on GPCR. William Blair reissued an “outperform” rating on shares of Structure Therapeutics in a report on Monday. Citigroup restated an “outperform” rating on shares of Structure Therapeutics in a report on Friday, December 12th. JPMorgan Chase & Co. upped their price target on shares of Structure Therapeutics from $65.00 to $105.00 and gave the stock an “overweight” rating in a research note on Thursday, January 22nd. Weiss Ratings reissued a “sell (d-)” rating on shares of Structure Therapeutics in a research report on Thursday, January 22nd. Finally, Guggenheim raised their price objective on shares of Structure Therapeutics from $90.00 to $140.00 and gave the company a “buy” rating in a research note on Tuesday, January 20th. Two investment analysts have rated the stock with a Strong Buy rating, thirteen have issued a Buy rating and two have assigned a Sell rating to the company’s stock. Based on data from MarketBeat, Structure Therapeutics currently has an average rating of “Moderate Buy” and a consensus target price of $110.00.

Structure Therapeutics Price Performance

The stock has a market cap of $3.57 billion, a PE ratio of -63.87 and a beta of -1.80. The company has a 50 day moving average price of $72.57 and a two-hundred day moving average price of $50.26.

Structure Therapeutics (NASDAQ:GPCR) last released its quarterly earnings data on Thursday, February 26th. The company reported ($0.49) earnings per share for the quarter, missing the consensus estimate of ($0.35) by ($0.14). As a group, equities analysts predict that Structure Therapeutics Inc. Sponsored ADR will post -0.82 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Structure Therapeutics

Several hedge funds and other institutional investors have recently modified their holdings of GPCR. PEAK6 LLC purchased a new position in shares of Structure Therapeutics in the 4th quarter worth $553,000. Flax Pond Capital LLC purchased a new stake in Structure Therapeutics during the fourth quarter valued at $3,389,000. XTX Topco Ltd bought a new position in Structure Therapeutics in the fourth quarter valued at about $1,335,000. Voloridge Investment Management LLC purchased a new position in Structure Therapeutics in the fourth quarter worth about $17,388,000. Finally, Vestal Point Capital LP purchased a new position in Structure Therapeutics in the fourth quarter worth about $2,434,000. 91.78% of the stock is owned by institutional investors.

About Structure Therapeutics

Structure Therapeutics (NASDAQ:GPCR) is a clinical‐stage biotechnology company focused on the discovery and development of oral small‐molecule therapies that target G protein‐coupled receptors (GPCRs). Leveraging advances in structural biology, computational chemistry and medicinal chemistry, the company’s scientific platform is designed to optimize binding interactions and pharmacokinetic properties, with the goal of delivering innovative treatments for metabolic and inflammatory disorders.

The company’s pipeline comprises multiple programs in various stages of preclinical and clinical development.